SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:1SXP - DE000A3ENQ51 - Common Stock
15.58 EUR
+0.16 (+1.04%)
Taking everything into account, 1SXP scores 6 out of 10 in our fundamental rating. 1SXP was compared to 22 industry peers in the Life Sciences Tools & Services industry. While 1SXP belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. 1SXP is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
1SXP had positive earnings in the past year.
In the past year 1SXP had a positive cash flow from operations.
Each year in the past 5 years 1SXP has been profitable.
In the past 5 years 1SXP always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of 9.16%, 1SXP belongs to the best of the industry, outperforming 86.36% of the companies in the same industry.
The Return On Equity of 1SXP (16.42%) is better than 86.36% of its industry peers.
1SXP has a better Return On Invested Capital (13.06%) than 86.36% of its industry peers.
The Average Return On Invested Capital over the past 3 years for 1SXP is significantly above the industry average of 9.34%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.16% | ||
| ROE | 16.42% | ||
| ROIC | 13.06% |
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
1.3 Margins
1SXP has a Profit Margin of 14.85%. This is in the better half of the industry: 1SXP outperforms 77.27% of its industry peers.
In the last couple of years the Profit Margin of 1SXP has grown nicely.
The Operating Margin of 1SXP (18.95%) is better than 72.73% of its industry peers.
1SXP's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 33.71%, 1SXP is doing worse than 63.64% of the companies in the same industry.
1SXP's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.95% | ||
| PM (TTM) | 14.85% | ||
| GM | 33.71% |
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), 1SXP is creating some value.
The number of shares outstanding for 1SXP remains at a similar level compared to 1 year ago.
The number of shares outstanding for 1SXP remains at a similar level compared to 5 years ago.
1SXP has a better debt/assets ratio than last year.
2.2 Solvency
The Debt to FCF ratio of 1SXP is 2.43, which is a good value as it means it would take 1SXP, 2.43 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 2.43, 1SXP belongs to the top of the industry, outperforming 90.91% of the companies in the same industry.
A Debt/Equity ratio of 0.09 indicates that 1SXP is not too dependend on debt financing.
With an excellent Debt to Equity ratio value of 0.09, 1SXP belongs to the best of the industry, outperforming 95.45% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 2.43 | ||
| Altman-Z | N/A |
ROIC/WACC1.45
WACC9.04%
2.3 Liquidity
A Current Ratio of 1.50 indicates that 1SXP should not have too much problems paying its short term obligations.
1SXP has a Current ratio of 1.50. This is in the better half of the industry: 1SXP outperforms 68.18% of its industry peers.
A Quick Ratio of 1.12 indicates that 1SXP should not have too much problems paying its short term obligations.
With a decent Quick ratio value of 1.12, 1SXP is doing good in the industry, outperforming 68.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.5 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
The earnings per share for 1SXP have decreased by -2.02% in the last year.
1SXP shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.78% yearly.
Looking at the last year, 1SXP shows a small growth in Revenue. The Revenue has grown by 3.04% in the last year.
The Revenue has been growing by 11.04% on average over the past years. This is quite good.
EPS 1Y (TTM)-2.02%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%0%
Revenue 1Y (TTM)3.04%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.44%
3.2 Future
The Earnings Per Share is expected to grow by 12.98% on average over the next years. This is quite good.
1SXP is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.13% yearly.
EPS Next Y5.75%
EPS Next 2Y11.1%
EPS Next 3Y11.63%
EPS Next 5Y12.98%
Revenue Next Year4.39%
Revenue Next 2Y6.84%
Revenue Next 3Y6.72%
Revenue Next 5Y7.13%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
1SXP is valuated correctly with a Price/Earnings ratio of 16.06.
Compared to the rest of the industry, the Price/Earnings ratio of 1SXP indicates a rather cheap valuation: 1SXP is cheaper than 90.91% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.25, 1SXP is valued a bit cheaper.
With a Price/Forward Earnings ratio of 15.19, 1SXP is valued correctly.
1SXP's Price/Forward Earnings ratio is rather cheap when compared to the industry. 1SXP is cheaper than 90.91% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of 1SXP to the average of the S&P500 Index (23.98), we can say 1SXP is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.06 | ||
| Fwd PE | 15.19 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1SXP is valued cheaper than 90.91% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, 1SXP is valued a bit more expensive than 68.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 66.73 | ||
| EV/EBITDA | 8.87 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
1SXP has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)2.8
PEG (5Y)1.17
EPS Next 2Y11.1%
EPS Next 3Y11.63%
5. Dividend
5.1 Amount
1SXP has a Yearly Dividend Yield of 1.18%.
In the last 3 months the price of 1SXP has falen by -21.71%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
1SXP's Dividend Yield is rather good when compared to the industry average which is at 0.54. 1SXP pays more dividend than 90.91% of the companies in the same industry.
Compared to the average S&P500 Dividend Yield of 1.92, 1SXP is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.18% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
16.45% of the earnings are spent on dividend by 1SXP. This is a low number and sustainable payout ratio.
DP16.45%
EPS Next 2Y11.1%
EPS Next 3Y11.63%
FRA:1SXP (1/12/2026, 5:29:59 PM)
15.58
+0.16 (+1.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners22.72%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.35B
Revenue(TTM)986.21M
Net Income(TTM)146.45M
Analysts75.79
Price Target23.9 (53.4%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.18% |
Yearly Dividend0.16
Dividend Growth(5Y)N/A
DP16.45%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2.27%
Min EPS beat(2)-3.5%
Max EPS beat(2)-1.05%
EPS beat(4)1
Avg EPS beat(4)-3.37%
Min EPS beat(4)-14.42%
Max EPS beat(4)5.48%
EPS beat(8)3
Avg EPS beat(8)1.1%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.13%
Min Revenue beat(2)-2.27%
Max Revenue beat(2)-1.99%
Revenue beat(4)1
Avg Revenue beat(4)-1.96%
Min Revenue beat(4)-5.31%
Max Revenue beat(4)1.75%
Revenue beat(8)3
Avg Revenue beat(8)0.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-16.41%
PT rev (3m)-20.68%
EPS NQ rev (1m)-6.61%
EPS NQ rev (3m)-14.29%
EPS NY rev (1m)-10.89%
EPS NY rev (3m)-15.27%
Revenue NQ rev (1m)-3.21%
Revenue NQ rev (3m)-5.48%
Revenue NY rev (1m)-4.21%
Revenue NY rev (3m)-5.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.06 | ||
| Fwd PE | 15.19 | ||
| P/S | 2.38 | ||
| P/FCF | 66.73 | ||
| P/OCF | 13.04 | ||
| P/B | 2.63 | ||
| P/tB | 2.72 | ||
| EV/EBITDA | 8.87 |
EPS(TTM)0.97
EY6.23%
EPS(NY)1.03
Fwd EY6.58%
FCF(TTM)0.23
FCFY1.5%
OCF(TTM)1.19
OCFY7.67%
SpS6.55
BVpS5.92
TBVpS5.72
PEG (NY)2.8
PEG (5Y)1.17
Graham Number11.37
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.16% | ||
| ROE | 16.42% | ||
| ROCE | 16.33% | ||
| ROIC | 13.06% | ||
| ROICexc | 13.46% | ||
| ROICexgc | 13.83% | ||
| OM | 18.95% | ||
| PM (TTM) | 14.85% | ||
| GM | 33.71% | ||
| FCFM | 3.57% |
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
ROICexc(3y)15.01%
ROICexc(5y)16.12%
ROICexgc(3y)15.5%
ROICexgc(5y)16.82%
ROCE(3y)18.26%
ROCE(5y)19.44%
ROICexgc growth 3Y-6.05%
ROICexgc growth 5Y-8.67%
ROICexc growth 3Y-5.65%
ROICexc growth 5Y-7.55%
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
F-Score6
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 2.43 | ||
| Debt/EBITDA | 0.3 | ||
| Cap/Depr | 182.22% | ||
| Cap/Sales | 14.68% | ||
| Interest Coverage | 11.84 | ||
| Cash Conversion | 67.54% | ||
| Profit Quality | 24.01% | ||
| Current Ratio | 1.5 | ||
| Quick Ratio | 1.12 | ||
| Altman-Z | N/A |
F-Score6
WACC9.04%
ROIC/WACC1.45
Cap/Depr(3y)260.7%
Cap/Depr(5y)265.72%
Cap/Sales(3y)16.46%
Cap/Sales(5y)16.64%
Profit Quality(3y)27.05%
Profit Quality(5y)27.58%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.02%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%0%
EPS Next Y5.75%
EPS Next 2Y11.1%
EPS Next 3Y11.63%
EPS Next 5Y12.98%
Revenue 1Y (TTM)3.04%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.44%
Revenue Next Year4.39%
Revenue Next 2Y6.84%
Revenue Next 3Y6.72%
Revenue Next 5Y7.13%
EBIT growth 1Y5.25%
EBIT growth 3Y3.6%
EBIT growth 5Y15.48%
EBIT Next Year43.48%
EBIT Next 3Y20.64%
EBIT Next 5Y16.53%
FCF growth 1Y-55.75%
FCF growth 3Y6.15%
FCF growth 5Y12.98%
OCF growth 1Y-19.95%
OCF growth 3Y-0.4%
OCF growth 5Y11.5%
SCHOTT PHARMA AG& CO KGAA / 1SXP.DE FAQ
Can you provide the ChartMill fundamental rating for SCHOTT PHARMA AG& CO KGAA?
ChartMill assigns a fundamental rating of 6 / 10 to 1SXP.DE.
What is the valuation status for 1SXP stock?
ChartMill assigns a valuation rating of 5 / 10 to SCHOTT PHARMA AG& CO KGAA (1SXP.DE). This can be considered as Fairly Valued.
How profitable is SCHOTT PHARMA AG& CO KGAA (1SXP.DE) stock?
SCHOTT PHARMA AG& CO KGAA (1SXP.DE) has a profitability rating of 8 / 10.
Can you provide the financial health for 1SXP stock?
The financial health rating of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 6 / 10.
What is the earnings growth outlook for SCHOTT PHARMA AG& CO KGAA?
The Earnings per Share (EPS) of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is expected to grow by 5.75% in the next year.